Candel Therapeutics, Inc.
CADL
$5.02
$0.6013.58%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 57.57% | 41.04% | -2.37% | -38.67% | -7.67% |
| Gross Profit | -57.57% | -41.04% | 2.37% | 38.67% | 7.67% |
| SG&A Expenses | 40.60% | 16.57% | 8.20% | 2.48% | 10.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.82% | 30.40% | 2.89% | -25.46% | -1.17% |
| Operating Income | -50.82% | -30.40% | -2.89% | 25.46% | 1.17% |
| Income Before Tax | -5.85% | 78.43% | 189.76% | -26.84% | -26.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.85% | 78.43% | 189.76% | -26.84% | -26.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.85% | 78.43% | 189.76% | -26.84% | -26.21% |
| EBIT | -50.82% | -30.40% | -2.89% | 25.46% | 1.17% |
| EBITDA | -52.87% | -31.40% | -3.06% | 26.08% | 1.21% |
| EPS Basic | 38.26% | 87.49% | 151.92% | -3.37% | -13.99% |
| Normalized Basic EPS | 38.26% | 87.49% | 151.93% | -1.47% | -13.99% |
| EPS Diluted | 38.26% | 87.49% | 146.16% | -3.37% | -13.99% |
| Normalized Diluted EPS | 38.26% | 87.49% | 147.84% | -1.47% | -13.99% |
| Average Basic Shares Outstanding | 71.47% | 72.33% | 72.90% | 22.71% | 10.70% |
| Average Diluted Shares Outstanding | 71.47% | 72.33% | 87.57% | 22.71% | 10.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |